Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03320434 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
A Phase 2 study of Allergic Conjunctivitis, sponsored by ORA.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT03320434: Completed Phase 2 study of Allergic Conjunctivitis, sponsored by ORA.
NCT03320434 is a Phase 2 study of Allergic Conjunctivitis that has completed, run by ORA. The registered enrollment target is 120 participants, roughly in line with the 129-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03320434, a Phase 2 study of Allergic Conjunctivitis, has completed, sponsored by ORA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the efficacy and safety of two concentrations of PRT-2761 as a topical ophthalmic solution for the treatment of the signs and symptoms of acute and chronic allergic conjunctivitis.
Primary Outcome
Ocular Itching was assessed by a trained investigator post-conjunctival allergen challenge (CAC) on a 0 to 4 scale (0=none (best/no itching) to 4=severe (worst/most itching). The ocular itching was averaged across all subjects at each time point.
Conditions Studied
Interventions
- DRUG PRT-2761 0.5%
- DRUG PRT-2761 1%
- DRUG Patanol
- DRUG Pred-forte
- DRUG PRT-2761 0%
Study Locations (1)
Massachusetts
- Andover Eye Associates - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-10-13 |
| Est. Completion | 2018-02-18 |
| Phase | Phase 2 |
What the finished NCT03320434 record still lists
NCT03320434 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 129-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 5 interventions - of which PRT-2761 0.5% is the first listed.
NCT03320434 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03320434 about?
NCT03320434 is a clinical study titled "Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis". To evaluate the efficacy and safety of two concentrations of PRT-2761 as a topical ophthalmic solution for the treatment of the signs and symptoms of acute and chronic allergic conjunctivitis.
What is the current status of trial NCT03320434?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2017-10-13. Estimated completion is 2018-02-18.
What conditions does trial NCT03320434 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT03320434?
The interventions under investigation include: PRT-2761 0.5% (DRUG), PRT-2761 1% (DRUG), Patanol (DRUG), Pred-forte (DRUG), PRT-2761 0% (DRUG).
Who is sponsoring clinical trial NCT03320434?
This trial is sponsored by ORA, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03320434 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03320434's enrollment target sits among peer trials
120 8th of 20 higher than 13 of 20 other Allergic Conjunctivitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergic Conjunctivitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
RECRUITING · Phase 2
-
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
RECRUITING · Phase 2
-
Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation
COMPLETED · Phase 2
-
Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
COMPLETED · Phase 2
-
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
COMPLETED · Phase 2
-
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI